iRegene Therapeutics's NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa

RegulatoryapprovedNouvSight001Positive

AI Analysis

Summary

iRegene Therapeutics received clearance to initiate clinical trials of NouvSight001, an off-the-shelf cell therapy for retinitis pigmentosa, in both the U.S. and China. This advance follows the company's earlier Parkinson's disease program into clinical development.

Clinical Trial Data

Outcome Details

Cleared for clinical trials in the U.S. and China

Importance:6/10

Sentiment:

0.70

cell therapyretinitis pigmentosaIND clearanceoff-the-shelf therapyU.S. regulatoryChina regulatory

Related Companies

$CHHE

Read the original article

Published by PR Newswire Biotech on September 29, 2026 5:41 AM

Read Original